Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 27, 2015 (11 years ago)

GRx HiCort 25

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Marketed without an Approved NDA/ANDA: FDA has determined that the products are unapproved new drugs and misbranded.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

GRx HiCort 25 (hydrocortisone acetate 25 mg) Suppositories, 12-count box, Rx only, Distributed by Geritrex Corporation Mount Vernon, NY 10550, NDC 54162-015-12

Affected NDC 54162-0015-12

Compare with the code on your package — it is the most precise check available.

Drug: Hydrocortisone

Recalling firm
Geritrex Corp
NDC code
54162-015-12
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0392-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydrocortisone recalls

See all
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026

Other recalls by Geritrex Corp

All 2015 recalls